Skip to main content
. Author manuscript; available in PMC: 2013 Aug 27.
Published in final edited form as: JACC Cardiovasc Imaging. 2012 May;5(5):540–549. doi: 10.1016/j.jcmg.2011.12.019

Table 4.

Clinical outcomes in the overall study population and in the groups with or without High On-Treatment Platelet Reactivity (HPR).

Overall group HPR No HPR P-value
n=335 n=109 n=226
MACE 18.2% (61/335) 22.9% (25/109) 15.9% (36/226) 0.132
Myocardial Infarction 0.9% (3/335) 0.9% (1/109) 0.9% (2/226) 1.000
TLR 17.9% (60/335) 22.9% (25/109) 15.5% (35/226) 0.128
Death 0.6% (2/335) 0.0% (0/109) 0.9% (2/226) 1.000

MACE = Major adverse cardiovascular events (death, myocardial infarction or TLR). No patient underwent coronary artery bypass graft surgery.